Inspection Record

Davis City Pharmacy Inc. — FDA 483 Findings

US FDAInspected 2022-02-18Published 2022-06-24 5 findingsLaboratory and QC controlsOther quality systemDocumentation and recordsContamination control

Inspectors Patty P Kaewussdangkul · Steven A BrettlerThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

2Other quality system

Unsealed, loose ceiling tiles were observed in your non-sterile "compounding lab".

3Documentation and records

Batch production and control records do not include complete information relating to the production and control of each batch.

4Contamination control

You produced highly potent drugs without providing adequate containment, segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

5Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

About this record

Extracted automatically from the document US FDA published on 2022-06-24. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Davis City Pharmacy Inc. company profile — full history US FDA documents, 2022 Go to Findings search